Evaluation of a Novel Single-Tube Method for Extended Genotyping of Human Papillomavirus
Authors:
Open Access
- 1 March 2018
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 56 (3) , e01687-17
Abstract
The use of high-risk human papillomavirus (HPV) testing for surveillance and clinical applications is increasing globally, and it is important that tests are evaluated to ensure they are fit for this purpose. In this study, the performance of a new HPV genotyping test, the Papilloplex high-risk HPV (HR-HPV) test, was compared to two well-established genotyping tests. Preliminary clinical performance was also ascertained for the detection of CIN2+ in a disease-enriched retrospective cohort. A panel of 500 cervical liquid-based cytology samples with known clinical outcomes were tested by the Papilloplex HR-HPV test. Analytical concordance was compared to two assays: a Linear Array (LA) HPV genotyping test and an Optiplex HPV genotyping test. The initial clinical performance for the detection for CIN2+ samples was performed and compared to that of two clinically validated HPV tests: a RealTime High-Risk HPV test (RealTime) and a Hybrid Capture 2 HPV test (HC2). High agreement for HR-HPV was observed between the Papilloplex and LA and Optiplex HPV tests (97 and 95%, respectively), with kappa values for HPV16 and HPV18 being 0.90 and 0.81 compared to the LA and 0.70 and 0.82 compared to the Optiplex test. The sensitivity, specificity, positive predictive value, and negative predictive value of the Papilloplex test for the detection of CIN2+ were 92, 54, 33, and 96%, respectively, and very similar to the values observed with RealTime and HC2. The Papilloplex HR-HPV test demonstrated a analytical performance similar to those of the two HPV genotyping tests at the HR-HPV level and the type-specific level. The preliminary data on clinical performance look encouraging, although further longitudinal studies within screening populations are required to confirm these findings.Keywords
Funding Information
- Innovate UK-Technology Strategy Board (101759)
- RCUK | Medical Research Council (mr/n005902/1)
This publication has 12 references indexed in Scilit:
- Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional studyThe Lancet Infectious Diseases, 2017
- Commercially available molecular tests for human papillomaviruses (HPV): 2015 updateJournal of Clinical Virology, 2016
- The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV TestCancer Epidemiology, Biomarkers & Prevention, 2015
- Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV typesBritish Journal of Cancer, 2014
- Global Improvement in Genotyping of Human Papillomavirus DNA: the 2011 HPV LabNet International Proficiency StudyJournal of Clinical Microbiology, 2014
- Disagreement between Human Papillomavirus Assays: An Unexpected Challenge for the Choice of an Assay in Primary Cervical ScreeningPLOS ONE, 2014
- Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impactBMC Infectious Diseases, 2013
- Multiplex Detection and SNP Genotyping in a Single Fluorescence ChannelPLOS ONE, 2012
- Comparison of Abbott RealTime High Risk HPV and Hybrid Capture 2 for the detection of high-risk HPV DNA in a referral population settingJournal of Clinical Virology, 2011
- Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and olderInternational Journal of Cancer, 2008